Login to Your Account

Novabiotics Raising $15M for Antimicrobial Drug Platform

By Nuala Moran
Staff Writer

Wednesday, March 14, 2012
LONDON – Novabiotics Ltd. is poised to close a $15 million funding round that will enable it to move its lead antimicrobial peptide product, Novexatin, into a Phase IIb trial in nail fungal infection onchomycosis and to advance its second program, Lynovex, into a Phase IIa trial in cystic fibrosis.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription